Biophytis (EPA:ALBPS)

PRESS RELEASE

published on 07/01/2024 at 07:00, 1 year 8 months ago

Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris
Biophytis presents positive results from Phase 2-3 COVA study for severe Covid-19 at WCID Paris. Bio101 shows significant efficacy and safety in reducing risk of respiratory failure and death

Biophytis COVID-19 Positive Results Phase 2-3 COVA Study Respiratory Failure
REGULATED PRESS RELEASE

published on 07/01/2024 at 07:00, 1 year 8 months ago

Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris
Biophytis presented positive results of its Phase 2-3 COVA study for severe Covid-19 at WCID in Paris, showing reduction in respiratory failure and death rates

Biophytis COVID-19 Positive Results Phase 2-3 COVA Study
BRIEF

published on 06/25/2024 at 23:05, 1 year 8 months ago

Biophytis Approves All Resolutions at General Meeting

Shareholders Biophytis General Meeting Resolutions
REGULATED PRESS RELEASE

published on 06/25/2024 at 23:00, 1 year 8 months ago

RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024
Biophytis SA announces the approval of all resolutions at the combined general meeting held on June 24, 2024, with significant shareholder participation

Shareholders General Meeting Resolutions Approval Biophytis SA
BRIEF

published on 06/20/2024 at 07:05, 1 year 9 months ago

Biophytis Grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at Up to €108 Million

Biophytis Pharmaceuticals Latin America BIO101 Blanver
PRESS RELEASE

published on 06/20/2024 at 07:00, 1 year 9 months ago

Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million
Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 million. Agreement includes upfront and milestones payments, double-digit royalties, and collaboration on manufacturing and clinical development

Biophytis Latin America Exclusive Rights Blanver Pharmaceutical Deal
REGULATED PRESS RELEASE

published on 06/20/2024 at 07:00, 1 year 9 months ago

Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million
Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million. Collaboration for commercialization and clinical development announced

Biophytis Latin America BIO101 Exclusive Rights Blanver
BRIEF

published on 06/20/2024 at 01:15, 1 year 9 months ago

Biophytis extends its contract with Atlas to finance its clinical activities

Biophytis Biotechnology Convertible Bonds Funding Atlas
PRESS RELEASE

published on 06/20/2024 at 01:10, 1 year 9 months ago

Biophytis extends its contract with Atlas to secure financing for its business activities
Biophytis extends financing agreement with Atlas, ensures funding for clinical programs OBA in obesity and MYODA in DMD. Details on the contract amendment and risk factors

Biophytis Atlas Financing Agreement Clinical Programs Risk Factors
BRIEF

published on 06/19/2024 at 23:05, 1 year 9 months ago

Biophytis Extends Financing Contract with Atlas

Biophytis Biotechnology Financing Clinical Trials Atlas

Published on 03/20/2026 at 23:00, 2 days 1 hour ago

Cypher Announces Private Placement
Published on 03/20/2026 at 21:30, 2 days 2 hours ago

Sky Gold Sets Options
Published on 03/20/2026 at 21:15, 2 days 2 hours ago

Earthwise Minerals Announces Private Placement
Published on 03/20/2026 at 13:30, 2 days 10 hours ago

Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 11 hours ago

CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals

View all ACCESSWIRE

Published on 03/22/2026 at 18:22, 5 hours 47 minutes ago

Test news - please ignore EN
Published on 03/22/2026 at 12:23, 11 hours 46 minutes ago

Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 2 days 1 hour ago

Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 2 days 3 hours ago

Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 2 days 3 hours ago

Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion

View all EQS

Published on 03/20/2026 at 19:00, 2 days 5 hours ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 18:15, 2 days 5 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 17:45, 2 days 6 hours ago

Cie du Bois Sauvage : Annual report 2025
Published on 03/20/2026 at 16:57, 2 days 7 hours ago

Number of shares and voting rights - February 2026 (In French only)
Published on 03/19/2026 at 18:00, 3 days 6 hours ago

Filing of the 2025 Universal Registration Document

View all LES ECHOS COMFI WIRE

News